Overview

Assessment of the Lipid Lowering Effect of Rosuvastatin Compared to Atorvastatin in Subjects With Coronary Heart Disease

Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy between two lipid lowering treatments, rosuvastatin (10-40 mg) and atorvastatin (20-80 mg) in reducing low-density lipoprotein cholesterol (LDL-C) levels after 16 weeks of treatment in patients with coronary heart disease
Phase:
Phase 4
Details
Lead Sponsor:
AstraZeneca
Treatments:
Atorvastatin
Atorvastatin Calcium
Clopidogrel
Rosuvastatin Calcium
Simvastatin